SMARCA4-deficient Malignant Tumors clinical trials at UCSF
1 research study open to eligible people
SMARCA4-deficient malignant tumors lack a vital protein that regulates cells. UCSF is researching whether using nivolumab and ipilimumab can treat these tumors in younger patients. The trial aims to observe the effects of these drugs on tumor progression.
Showing trials for
Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
open to eligible people ages 6 months to 40 years
This clinical trial is studying two immunotherapy drugs (nivolumab and ipilimumab) given together as a possible treatment for INI1-negative tumors.
San Francisco, California and other locations
Our lead scientists for SMARCA4-deficient Malignant Tumors research studies include Alyssa Reddy.
Last updated: